Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's a very precision orientationted exec team. But that's what you want when cross swords with the FDA approval process.
Monday will be huge for $ADAC. Get in before the massive pop.
Up 3% green is not a bad way to close the week but the potential her is so much deeper
Exactly right.
Yeah but that estimate has to be revised per the last PR. Now we know that the IRB hurdle had not yet been overcome. IRB clearance to begin clinical studies was only received this week. So know I would estimate 6 months from the week at the most till FDA clearance then commercialization.
How frustrating is that? And with solid volume and more buys we close at .417? MM s need a kick in the head.
$ADAC just a half a tick away from HOD at 9 cents. 10 cent breakout big psychological significance and it should really run after that.
Blue sky breakout! $ADAC patience pays off at last
$ADAC breakout to 9! 10 is within range!
Time for $LXGTF to break out above this range bound trading.
That's right this is definitely a HODL.
And LXGTF HeartSentry does not require a clinical setting with trained medical personal to operate. It can be successfully used by ordinary consumers in thier own homes.
30% plus of ALL deaths are caused by heart attack and stroke. Current diagnostic standards fail dismally in alerting potentiality victims. Where BP monitoring and chloresterol tests have failed, LXGTF HeartSentry succeeds.
Most importantly HeartSentry monitor will save lives by using endothelial diagnostics to avert heart attack and stroke.
$LXGTF HeartSentry monitor is groundbreaking in every sense of the term: cutting edge science, portability, ease of use, affordability etc.
$LXGTF passed IRB and clinical tests have commenced.
Morning LXGTF nice to be up 3% green.
Let's breakout past 10 $ADAC!
Hi volume right out the gate.
$2million in Revs really got the markets attention.
Wow! Yesterday was quite the pop!
Good morning $ADAC!
Yup the the time is ripe for HeartSentry. That's all for me. See you guys in the morning. Bye!
Neither Ultrasound or Endopat present any real utility as a front line, convenient, routine diagnostic tool. By the time the insurance company approves that kind of clinical test, you're already sick and in trouble. LXGTF HeartSentry can be bought affordable and operated by grandma at the kitchen table.
90% of the way to market it seems.
If we get word of a buyout this will go parabolic.
It actually could explain some of the selling today. When they announced they had applied for the IRB some whales probably started quietly accumulating in anticipation of the approval announcement.
The HeartSentry tech is the begining of a new era in heart attack and stroke prevention. Its needed: 30% of all deaths are due to those diseases and we've not had an upgrade in effective routine diagnostics in decades.
GOOD NEWs Yesterday: Lexington Recieves Approval to Commence Clinical Study
GlobeNewswire•24 January 2018
VANCOUVER, British Columbia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE:LNB) (LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce its recent application for Institutional Review Board (“IRB”) approval of its pilot clinical study at Diablo Clinical Research has been approved.
As previously noted, approval by an IRB, or ethics board, is necessary before human research can begin. The IRB has reviewed Lexington’s submission for both medical safety and protection of the patients involved in the study and has subsequently advised of its approval as submitted. With approval in-hand, the Company has engaged a clinical investigative team and research site in preparation for the process of volunteer enrollment.
Lexington’s President Eric Willis comments, “The rapid approval of our clinical study submission speaks volumes to our team’s diligent attention to the design of the product and required documentation, as well as the format of the proposed study itself. We are planning to immediately move ahead into the investigative phase of our studies aimed at achieving eventual FDA clearance for our HeartSentry device. This means we are proceeding rapidly toward our strategic goals. Our thorough planning means we are also in great shape to act on the approval right away. We are very happy to begin this most critical phase of our development to-date and look forward to the work ahead.”
To find out more about Lexington Biosciences, interested readers are invited to visit our website and view our video featuring principal HeartSentry inventor Dr. Jonathan Maltz, Ph.D., which provides an excellent overview of our business proposition and opportunity ahead. Please also follow us on Facebook, Twitter and LinkedIn.
About Lexington Biosciences, Inc. (CSE: LNB / OTCQB: LXGTF)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium - the vital innermost lining of a person’s cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit: https://lexingtonbiosciences.com/.
On Behalf of the Board,
“Eric Willis”
Eric Willis
CEO & Director
About Lexington Biosciences, Inc. (CSE: LNB / OTCQB: LXGTF)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium - the vital innermost lining of a person’s cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit: https://lexingtonbiosciences.com/.
You ever saw an IHUB board swarming with posters while the price plummeted? Me too. Fake hype is the order for the day on IHUB. In contrast to that this ticker is legit. It used to trade around half a buck before they got behind on fliings, they got all caught up and have some profitable initiatives going on. $2 million in revenues for just one of their subsidiaries. Check out the last PR https://finance.yahoo.com/news/adama-technologies-corp-announces-revenue-140000311.html
Longs are planking in a new support level with all the cheap shares before the next leg up.
$ADAC closed up green 67% on 2.2 mil shares in volume.
$2 mil in contract revs for Alpine and an additional $1.2 in possible new contracts bid on this month. 2018 is a good year to be holding defense contracts with the Air Force. $ADAC
The light at the end of the tunnel is this iron clad support we have here at .40. Just too much grass roots retail behind $LXGTF. Its not going down from here. As we get more updates on clinicals this will pop up past 50's, 60's for sure.
Bunch of morons, anyone selling before FDA clearance here has just not read the DD, they are only looking at a ticker symbol.
Just watch we have some solid gold support at .40. They won't let it slip. $LXGTF will bounce.
Churning in the low 40s on solid early volume $LXGTF.
Its the real deal: $400k in Q1 this year, $2mil more anticipated from their existing Air Force contracts in 2018, and $1.2 mil more in potential new contracts that have been bid on so far this year.